Sign in
Not yet taking people in South KoreaNo phase

CHANK-101 natural killer cell therapy for recurrent glioblastoma

Tests CHANK-101, made from patients' own immune cells, in adults with recurrent glioblastoma.

Key facts

Who runs it
Dong-A University Hospital
Where
Busan, Seongnam-si, and Seoul, South KoreaSee the 4 sites
Trial code
Registry title
Safety and Efficacy of Autologous Natural Killer Cell Therapy (CHANK-101) in Patients With Recurrent Glioblastoma
Status
Not yet recruiting
People taking part
60 people, planned
Starts
29 Nov 2026
Expected to end
31 Mar 2028
Type of study
Interventional
Treatments tested
  • CHANK-101
Record updated
2 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with IDH-wildtype glioblastoma that has come back for the first time after standard first treatment.

Age
19 years to less than 70 years
Sex
Men and women
Disease stage
Glioblastoma (WHO Grade 4, IDH-wildtype) in first recurrence, after surgery, radiotherapy and temozolomide (TMZ) treatment.
Earlier treatment
Must have finished standard first treatment: surgery, radiotherapy with TMZ, then 6 cycles of TMZ. No cancer treatment other than surgery since the recurrence was confirmed.
Biomarker or test result
IDH-wildtype glioblastoma confirmed by tissue examination.

Main reasons for not taking part

  • Two or more recurrences, or earlier treatment for a previous recurrence
  • Glioblastoma spread to the brain lining fluid spaces or outside the skull
  • Need for long-term high-dose steroids or other immune-suppressing drugs
  • Another cancer within the past 3 years (some skin and cervical cancers excepted)
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • Male or female adults aged 19 years to less than 70 years who have received sufficient explanation regarding the purpose, methods, potential benefits, and risks of the study and have voluntarily provided written informed consent
  • Histologically confirmed IDH-wildtype glioblastoma (GBM), WHO Grade 4, according to the WHO CNS5 2021 classification
  • Completion of standard first-line treatment (surgery + radiotherapy + concurrent TMZ → 6 cycles of adjuvant TMZ)
  • Confirmed first recurrence, defined by at least one of the following:; (1) Progressive Disease according to RANO 2.0 criteria on MRI more than 12 weeks after completion of radiotherapy; (2) If within 12 weeks after completion of radiotherapy, pseudoprogression has been excluded through the RANO 2.0 confirmation procedure (confirmatory scan), and persistent progression has been confirmed on two consecutive scans at least 4 weeks apart
  • No antitumor treatment, including chemotherapy, immunotherapy, targeted therapy, or radiotherapy, after confirmation of recurrence, except surgery
  • KPS ≥ 60
  • Adequate organ function permitting study treatment and surgery, including:
  • Absolute neutrophil count (ANC) ≥ 1.5 × 10\^9/L
  • Platelets ≥ 100 × 10\^9/L
  • Hemoglobin (Hb) ≥ 9.0 g/dL
  • AST and ALT ≤ 2.5 × ULN
  • Total bilirubin ≤ 1.5 × ULN
  • Serum creatinine ≤ 1.5 × ULN or eGFR ≥ 50 mL/min/1.73 m\^2
  • Adequate peripheral venous access for leukapheresis or ability to undergo central venous catheter placement
  • Life expectancy of at least 12 weeks, as determined by the investigator
  • Female participants who are postmenopausal, defined as 12 months of amenorrhea without a medical cause, or women of childbearing potential with a negative pregnancy test
  • Women of childbearing potential and male participants who agree to use appropriate contraception (e.g., condoms, hormonal contraceptives, oral contraceptives, intrauterine devices, or sterilization) during the study and for 3 months after the last administration of the study treatment

Who cannot take part

  • Two or more recurrences or prior antitumor treatment for a previous recurrence
  • Requirement for chronic high-dose systemic corticosteroids (e.g., >10 mg/day prednisolone equivalent) or continuous use of other immunosuppressive drugs. Low-dose corticosteroid use at enrollment is permitted; however, the washout criteria must be met at each study treatment administration
  • Active autoimmune disease requiring systemic immunosuppressive treatment within the past 2 years (e.g., steroids ≥10 mg/day prednisolone equivalent or immunosuppressive agents). Exceptions include adequately treated Basedow/Graves disease or Hashimoto thyroiditis with stable thyroid hormone replacement therapy, vitiligo, resolved childhood asthma, type 1 diabetes, and localized skin disorders
  • A positive result for any of the following infectious disease tests performed at screening. However, participants with a positive result may participate if the investigator determines that it has no clinically significant impact on participation in the study:; (1) HBsAg/HBV NAT. (2) HCV Ab/HCV NAT. (3) HIV Ab/HIV NAT. (4) Syphilis (non-treponemal/treponemal). (5) HTLV Ab. (6) CMV Ab/CMV NAT
  • Uncontrolled active infection or any other infectious disease considered by the investigator to be inappropriate for participation in the study
  • History of another malignancy within the past 3 years, except adequately treated basal cell or squamous cell carcinoma of the skin or cervical carcinoma in situ
  • Contraindication to leukapheresis (e.g., severe cardiovascular disease or coagulation disorder)
  • Serious medical or psychiatric condition that may affect participation in the study
  • History of a severe allergic reaction or other serious hypersensitivity to the study treatment or any of its excipients
  • Confirmed leptomeningeal dissemination or extracranial metastasis
  • Pregnant or breastfeeding women
  • Participants planning pregnancy during the study
  • Participants considered by the investigator unlikely to comply with study treatment, study procedures, or follow-up
  • Any other participant considered by the investigator to be unsuitable for participation in the study

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 19 and 69 years old?

Where in South Korea

  • Dong-A University HospitalBusan, South KoreaContact: Kyoungsu Sung, MDNot yet recruiting
  • CHA Bundang Medical CenterSeongnam-si, South KoreaContact: Jaejoon Lim, MD, PhDNot yet recruiting
  • Asan Medical CenterSeoul, South KoreaContact: ChangKi Hong, MD, PhDNot yet recruiting
  • Gangnam Severance HospitalSeoul, South KoreaContact: Jihwan Yoo, MDNot yet recruiting

About the trial

What the trial wants to find out

This multicenter, open-label, externally controlled clinical study is designed to evaluate the safety and efficacy of CHANK-101, an autologous natural killer (NK) cell therapy, in patients with recurrent glioblastoma. The primary objective is to evaluate progression-free survival (PFS) following CHANK-101 administration. Secondary objectives include evaluating safety and tolerability, progression-free survival at 6 months (PFS-6), and overall survival (OS).

The group in the trial

  • CHANK-101 Treatment GroupTreatment being tested

    Participants will receive CHANK-101, an autologous natural killer (NK) cell therapy, by intravenous administration. The first administration will begin 4 to 6 weeks after leukapheresis, or 4 to 6 weeks after surgery for participants undergoing surgical resection of the recurrent lesion. CHANK-101 will subsequently be administered every 2 weeks for up to 12 administrations.

    Treatment: CHANK-101

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Multicenter, Open-label, Externally Controlled Clinical Study to Evaluate the Safety and Efficacy of Autologous Natural Killer Cell (CHANK-101) in Patients With Recurrent Glioblastoma
Plain-language title
CHANK-101 natural killer cell therapy for recurrent glioblastomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Criteria questions
Built from NCT07831161, who can take part
Record updated
2 November 2026